<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00648258</url>
  </required_header>
  <id_info>
    <org_study_id>VALA-0513-141</org_study_id>
    <secondary_id>A3471101</secondary_id>
    <nct_id>NCT00648258</nct_id>
  </id_info>
  <brief_title>A Double-Blind, Double Dummy, Randomized Comparison Study Of The Efficacy And Safety Of Valdecoxib 10mg Once Daily And Naproxen 500mg Twice Daily In Treating The Signs And Symptoms Of Osteoarthritis Of The Knee Or Hip In Taiwan</brief_title>
  <official_title>A Double-Blind, Double Dummy, Randomized Comparison Study Of The Efficacy And Safety Of Valdecoxib 10mg QD And Naproxen 500mg BID In Treating The Signs And Symptoms Of Osteoarthritis Of The Knee Or Hip In Taiwan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy, safety, and tolerability of valdecoxib by comparing valdecoxib 10
      mg daily (QD) with naproxen 500 mg twice daily (BID) in treating the signs and symptoms of
      osteoarthritis (OA) of the knee or hip. The study was designed to collect comparative
      information for the local population (Taiwan).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">April 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient's Assessment of Arthritis Pain (Osteoarthritis-Pain VAS)</measure>
    <time_frame>Week 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Western Ontario and McMaster Universities Osteoarthritis (WOMAC OA) Composite Index</measure>
    <time_frame>Week 2 and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC OA physical function</measure>
    <time_frame>Week 2 and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC OA pain index</measure>
    <time_frame>Week 2 and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC OA stiffness index</measure>
    <time_frame>Week 2 and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Assessment of Arthritis Pain (Osteoarthritis-Pain VAS)</measure>
    <time_frame>Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Assessment of Arthritis</measure>
    <time_frame>Week 2 and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's Global Assessment of Arthritis</measure>
    <time_frame>Week 2 and Week 6</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valdecoxib</intervention_name>
    <description>valdecoxib 10 mg tablet by mouth once daily for 6 weeks</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naproxen</intervention_name>
    <description>naproxen 500 mg capsule by mouth twice daily for 6 weeks</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The diagnosis of hip OA, which was having hip pain and meeting criteria for at least 2
             of the following: a. Westergren erythrocyte sedimentation rate of &lt; 20 mm/hr; b.
             radiographic femoral or acetabular osteophytes or c. radiographic joint space
             narrowing

          -  Knee OA diagnosis required diagnosing (by modified American College of Rheumatology
             criteria) OA of the knee with pain plus at least one of the following: a. Age&gt; 50
             years old, b. Stiffness &lt; 30 minutes, c. crepitus on active motion and radiographic
             evidence of OA of the knee, defined as presence of osteophytes or joint space
             narrowing

          -  Symptomatic OA of the knee or hip was determined at the Baseline Visit, if the
             Patient's Assessment of Arthritis Pain was at least 40 mm VAS, Patient's and the
             Physician's Global Assessment of Arthritis was &quot;poor&quot; or &quot;very poor&quot;

        Exclusion Criteria:

          -  Use of NSAIDs or analgesics within 2 days (within 4 days for subjects taking
             oxaprozin, piroxicam or full dose aspirin) before baseline arthritis assessments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kweishan</city>
        <state>Taoyuan</state>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=VALA-0513-141&amp;StudyName=A%20Double-Blind%2C%20Double%20Dummy%2C%20Randomized%20Comparison%20Study%20Of%20The%20Efficacy%20And%20Safety%20Of%20Valdecoxib%2010mg%20Once%20Daily%20And%20Naproxen</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2008</study_first_submitted>
  <study_first_submitted_qc>March 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2008</study_first_posted>
  <last_update_submitted>April 7, 2008</last_update_submitted>
  <last_update_submitted_qc>April 7, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2008</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>osteoarthritis, knee</keyword>
  <keyword>osteoarthritis, hip</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
    <mesh_term>Signs and Symptoms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Valdecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

